stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Book value per share
NeoGenomics, Inc.'s book value per share at the end of fiscal 2025 was 6.5×, down 8.33% from 7.1× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 6.2×. Over the past ten years it has ranged from 2.1× (fiscal 2016) to 9.2× (fiscal 2021); the current reading is higher than 64% of that period. NeoGenomics, Inc. ranks 25th of 49 Diagnostics & Research companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.5× | (8.33%) |
| FY2024 | 7.1× | (5.04%) |
| FY2023 | 7.5× | (6.63%) |
| FY2022 | 8.0× | (13.03%) |
| FY2021 | 9.2× | 44.48% |
| FY2020 | 6.4× | 26.61% |
| FY2019 | 5.1× | 34.94% |
| FY2018 | 3.7× | 72.86% |
| FY2017 | 2.2× | 2.54% |
| FY2016 | 2.1× | (39.00%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 6.2× | 2.72% |
| Jun 2026 | 6.1× | (5.53%) |
| Mar 2026 | 6.4× | (1.75%) |
| Dec 2025 | 6.5× | 0.04% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| VCYT Veracyte, Inc. compare | 17.8× |
| CSTL Castle Biosciences, Inc. compare | 15.6× |
| CDNA CareDx, Inc. compare | 9.0× |
| WGS GeneDx Holdings Corp. compare | 8.2× |
| NEO NeoGenomics, Inc. | 6.2× |
| PSNL Personalis, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 1.5× |
| ADPT Adaptive Biotechnologies Corporation compare | 1.1× |
| FRNM Freenome, Inc compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement